Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedNaples, Italy, 80131 has been added as a study location and Napoli, Italy, 80131 removed; the study revision version updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This is a metadata version change and does not alter the study details displayed.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.0%

- Check82 days agoChange Detected- Revision: v3.3.4 updated (replacing v3.3.3). The overall study information on the page remains unchanged.SummaryDifference0.0%

- Check104 days agoChange DetectedAdded a Locations section with a comprehensive list of study sites across the US and Australia; previous location entries were removed.SummaryDifference1%

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.